DCDinna N. Cruz

Dinna N. Cruz

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Dinna N. Cruz has a total of 161 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Acute kidney injury in the elderly

    by Dinna N. Cruz, Anna Clementi, Mitchell H. Rosner

    Acute kidney injury (AKI) is largely a disease of the elderly patient. As described in this chapter, age-related changes in the kidney as well as the accumulated co-morbid conditions and polypharmacy associated with ageing greatly increase the susceptibility to the development of AKI. The aetiologies of AKI in the elderly patient represent the same spectrum of prerenal, intrarenal, and postrenal causes as in other age categories. However, elderly patients tend to have a higher relative risk for developing AKI due to volume depletion and urinary tract obstruction. Diagnosis of AKI can be confounded by the use of serum creatinine which has limitations in the diagnosis of AKI.Poorer short- and long-term outcomes may influence decision-making on the provision of aggressive care such as offering renal replacement therapy. These complex decisions require a careful analysis of potential outcomes as well as coordinated discussions with family members to ensure that the most thoughtful and rational treatments are offered.


  • Acute kidney injury in the elderly

    by Dinna N. Cruz, Anna Clementi, Mitchell H. Rosner

    • 21 June 2015
      • Vol. 32  (3)

    [Plasma NGAL and ADPKD progression].

    by Grazia Maria Virzì, Fiorella Gastaldon, Valentina Corradi, Massimo De Cal, Dinna N Cruz, Maurizio Clementi, Claudio Ronco

    Autosomal dominant polycystic kidney disease (ADPKD) is a genetic disease with variable rate of progression. It is associated with inter- and intra-familial variability. Neutrophil gelatinase-associated lipocalin (NGAL) has been implicated in pathological conditions and it is proposed as a biomarker for CKD progression. Our aim was to evaluate whether NGAL could be a good marker for progression of ADPKD, as we hypothesized. ADPKD patients with confirmed mutations (PKD1 n=33; PKD2 n=17) were enrolled and followed in a prospective study. Creatinine (sCr) and NGAL values were measured at baseline and on follow-up. Plasma NGAL was measured by Triage point of care test. CKD progression was defined as 15% decrease in eGFR from baseline to follow-up. Patients were divided into 2 groups based on median baseline NGAL and compared by the Kaplan-Meier curve. We enrolled 50 ADPKD pts (60%M age 41 yrs); mean sCr 1.30.7 mg/dl and median eGFR was 62 mL/min/1.73 m2. NGAL values are inversely correlated with baseline eGFR (r=-0.64, p<0.001). There was weak correlation between baseline NGAL and subsequent change in eGFR (r=0.28, p=0.05). 9/50 of patients had NGAL below limits of detection (60 pg/ml); median NGAL level was 79 pg/ml. At follow-up, 12 patients (24%) had progression as defined. No statistically significant relationship between higher NGAL and ADPKD progression was observed. We did not observe a relationship between NGAL and CKD progression in ADPKD patients; however 18% of patients had undetectable plasma NGAL levels. This raises doubt about the utility of the current NGAL assay as a biomarker for CKD progression in this population.


  • Acute Kidney Injury Biomarkers

    by Marlies Ostermann, Dinna Cruz, Hilde H. R. De Geus


    • 20 June 2014
      • Vol. 30  (4)

    [Genotype-phenotype correlation in ADPKD: a possible role for NGAL?].

    by Grazia Maria Virzì, Fiorella Gastaldon, Valentina Corradi, Massimo De Cal, Dinna N Cruz, Maurizio Clementi, Claudio Ronco

    Autosomal dominant polycystic kidney disease (ADPKD) is the most common genetic cause of chronic kidney disease (CKD) in adults. It is associated with both inter- and intra- familial variability, which can be explained by genetic heterogeneity, modifier genes and a genetic background. NGAL, a 25-kDa protein released from tubular cells after harmful stimuli, is a new biomarker. Recent studies suggest a possible role for NGAL in CKD. The aim of this study was to investigate NGAL in the context of genotype-phenotype correlation in ADPKD. We measured plasma NGAL, creatinine (Cr), and urea in 18 ADPKD patients on dialysis (PKD1_TRS), 29 of their relatives with CKD stage II-III (PKD1_AMB), 33 wild-type relatives (PKD1_WT), 12 subjects in CKD stage II-III with confirmed mutation in PKD2 and 30 healthy controls (CTR). Cr, urea and CysC were measured according to standard methods. Plasma NGAL was measured using point-of-care test. Estimated glomerular filtration rate (eGFR) was calculated with a 4-variable standardized-MDRD formula. Plasma NGAL, CysC, Cr and urea levels in PKD1_TRS were significantly higher than CTR (all with p0.05). NGAL levels were not significantly different in ADPKD patients in CKD stage II-III with mutation in PKD1 or PKD2 (86 pg/mL, IQR 60-109 vs 82 pg/mL,IQR 63-169). NGAL correlated well (all with p<0.001) with CysC (r=0.95), Cr (r=0.89), urea (r=0.76) and inversely with eGFR (r=-0.81). A strong correlation between CysC and residual renal function was observed (CysC/eGFR: r=-0.86; CysC/Cr: r=0.7; CysC/Urea: r=0.79, all with p<0.001). This is the first study to evaluate plasma NGAL in the context of genotype-phenotype correlation. In ADPKD, NGAL levels were higher in patients already on Renal Replacement Therapy (RRT) compared to their affected relatives not on RRT. WT relatives had normal NGAL and CysC levels: these could be considered a better CTR group because they share the same genetic background with ADPKD subjects. No differences were found in NGAL levels between PKD1 and PKD2 patients in CKD stage II-III. Furthermore, the results indicate that NGAL correlates closely with renal function and CysC levels.


  • Open Access

    Utilization of Small Changes in Serum Creatinine with Clinical Risk Factors to Assess the Risk of AKI in Critically lll Adults

    by Dinna N. Cruz, Asunción Ferrer-Nadal, Pasquale Piccinni, Stuart L. Goldstein, Lakhmir S. Chawla, Elisa Alessandri, Clara Belluomo Anello, Will Bohannon, Tiziana Bove, Nicola Brienza, et al.

    Background and objectives Disease biomarkers require appropriate clinical context to be used effectively. Combining clinical risk factors, in addition to small changes in serum creatinine, has been proposed to improve the assessment of AKI. This notion was developed in order to identify the risk of AKI early in a patient9s clinical course. We set out to assess the performance of this combination approach. Design, setting, participants, & measurements A secondary analysis of data from a prospective multicenter intensive care unit cohort study (September 2009 to April 2010) was performed. Patients at high risk using this combination approach were defined as an early increase in serum creatinine of 0.1–0.4 mg/dl, depending on number of clinical factors predisposing to AKI. AKI was defined and staged using the Acute Kidney Injury Network criteria. The primary outcome was evolution to severe AKI (Acute Kidney Injury Network stages 2 and 3) within 7 days in the intensive care unit. Results Of 506 patients, 214 (42.2%) patients had early creatinine elevation and were deemed at high risk for AKI. This group was more likely to subsequently develop the primary endpoint (16.4% versus 1.0% [not at high risk], PP<0.001). Conclusion Critically ill patients at high AKI risk, based on the combination of clinical factors and early creatinine elevation, are significantly more likely to develop severe AKI. As initially hypothesized, the high-risk combination group methodology can be used to identify patients at low risk for severe AKI in whom AKI biomarker testing may be expected to have low yield. The high risk combination group methodology could potentially allow clinicians to optimize biomarker use.


  • Open Access

    Effects of fluid overload on heart rate variability in chronic kidney disease patients on hemodialysis

    by Manuela Ferrario, Ulrich Moissl, Francesco Garzotto, Dinna N Cruz, Anna Clementi, Alessandra Brendolan, Ciro Tetta, Emanuele Gatti, Maria G Signorini, Sergio Cerutti, et al.

    While fluid overload (FO) and alterations in the autonomic nervous system (ANS) such as hypersympathetic activity, are known risk factors for cardiovascular morbidity and mortality in patients on chronic hemodialysis (HD), their relationship has not been thoroughly studied. In this observational study involving 69 patients on chronic HD, FO was assessed by whole body bioimpedance measurements before the midweek HD session and ANS activity reflected by Heart Rate Variability (HRV) was measured using 24-hour Holter electrocardiogram recordings starting before the same HD treatment. In total, 13 different HRV indices were analyzed, comprising a mixture of time domain, frequency domain and complexity parameters. A correlation analysis was performed between the HRV indices and hydration status indices. Successively, patients were retrospectively assigned to a high FO (H, FO > 2.5 L) or low FO (L, FO ≤ 2.5 L) group and these were further compared also after stratification by diabetes mellitus. Finally, a small number of patients without diabetes with significant and persistent FO were followed up for 3 months post-study to investigate how normalization of fluid status affects HRV. SDANN, VLF, LZC and HF% parameters significantly correlate with FO (correlation coefficients were respectively r = –0.40, r = –0.37, r = –0.28 and r = 0.26, p-value < 0.05). Furthermore, LF% and LF/HF were inversely correlated with hydration status (correlation coefficients were respectively r = –0.31 and r = -0.33, p-value < 0.05). These results indicate an association between FO and reduced HRV, higher parasympathetic activation and reduced sympathetic response to the HD session. Indeed, group H tended to have lower values of SDANN, VLF and LZC, and higher values of HF% than patients in the L group. Finally, there was a trend towards lower LF% measured during the last 30 minutes of HD for the H group versus the L group. Reduction in FO achieved over 3 months by implementation of a strict fluid management plan resulted in an increase of HRV. Our results suggest that depressed HRV is associated with fluid overload and that normalization of hydration status is accompanied by improved HRV.


  • Open Access

    Use of Peritoneal Dialysis in AKI

    by Chang Yin Chionh, Sachin S. Soni, Fredric O. Finkelstein, Claudio Ronco, Dinna N. Cruz

    Summary: Background and objectives: The role of peritoneal dialysis in the management of AKI is not well defined, although it remains frequently used, especially in low-resource settings. A systematic review was performed to describe outcomes in AKI treated with peritoneal dialysis and compare peritoneal dialysis with extracorporeal blood purification, such as continuous or intermittent hemodialysis. Design, setting, participants, & measurements: MEDLINE, CINAHL, and Central Register of Controlled Trials were searched in July of 2012. Eligible studies selected were observational cohort or randomized adult population studies on peritoneal dialysis in the setting of AKI. The primary outcome of interest was all-cause mortality. Summary estimates of odds ratio were obtained using a random effects model. Results: Of 982 citations, 24 studies (n=1556 patients) were identified. The overall methodological quality was low. Thirteen studies described patients (n=597) treated with peritoneal dialysis only; pooled mortality was 39.3%. In 11 studies (7 cohort studies and 4 randomized trials), patients received peritoneal dialysis (n=392, pooled mortality=58.0%) or extracorporeal blood purification (n=567, pooled mortality=56.1%). In the cohort studies, there was no difference in mortality between peritoneal dialysis and extracorporeal blood purification (odds ratio, 0.96; 95% confidence interval, 0.53 to 1.71). In four randomized trials, there was also no difference in mortality (odds ratio, 1.50; 95% confidence interval, 0.46 to 4.86); however, heterogeneity was significant (I 2=73%, P=0.03). Conclusions: There is currently no evidence to suggest significant differences in mortality between peritoneal dialysis and extracorporeal blood purification in AKI. There is a need for good-quality evidence in this important area.


  • Incidence, Risk Factors, and Outcome

    by Mitchell H. Rosner, Claudio Ronco, Dinna N. Cruz